Effective treatment of aspergillosis: A Synthesis of Findings from 32 Studies

  1. Home
  2. Effective treatment of aspergillosis
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effective treatment of aspergillosis: A Synthesis of Findings from 32 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effective treatment of aspergillosis: A Synthesis of Findings from 32 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Key Research Findings

Several key findings have been reported regarding the role of combination antifungal therapy in the treatment of aspergillosis. 13 suggests that clinicians have resorted to the use of combination antifungal therapy due to suboptimal treatment outcomes for invasive aspergillosis (IA). 22 suggests that a therapeutic strategy using nebulized liposomal amphotericin B (LAmB) for Allergic bronchopulmonary aspergillosis (ABPA) could increase antifungal drug concentration in lung tissue, circumvent drug interactions, and decrease the potential toxicity of systemic antifungal treatments. Moreover, and 18 highlight the importance of early diagnosis and treatment of aspergillosis in immunocompromised individuals, emphasizing the need for research into new diagnostic tools and drug treatment strategies.

Treatment Summary

13 suggests that clinicians have resorted to the use of combination antifungal therapy due to suboptimal treatment outcomes for invasive aspergillosis (IA). 22 suggests that a therapeutic strategy using nebulized liposomal amphotericin B (LAmB) for Allergic bronchopulmonary aspergillosis (ABPA) could increase antifungal drug concentration in lung tissue, circumvent drug interactions, and decrease the potential toxicity of systemic antifungal treatments. and 18 emphasize the importance of early diagnosis and treatment of aspergillosis in immunocompromised individuals.

Benefits and Risks

Benefit Summary

Combination antifungal therapy may improve treatment outcomes for aspergillosis. 13 . A therapeutic strategy using nebulized liposomal amphotericin B (LAmB) for Allergic bronchopulmonary aspergillosis (ABPA) could increase antifungal drug concentration in lung tissue, circumvent drug interactions, and decrease the potential toxicity of systemic antifungal treatments. 22 . Early diagnosis and treatment may improve patient survival. , 18 .

Risk Summary

Combination antifungal therapy may carry the risk of side effects. 13 . A therapeutic strategy using nebulized liposomal amphotericin B (LAmB) for Allergic bronchopulmonary aspergillosis (ABPA) has not been sufficiently researched, and the long-term safety is unknown. 22 .

Comparison Between Studies

Commonalities Between Studies

Many studies emphasize the importance of early diagnosis and treatment of aspergillosis. 13 , , 18 . They also call for the development of combination antifungal therapy and new treatment approaches. 13 , 22 .

Differences Between Studies

Studies differ in terms of their subjects and treatment approaches. For example, 13 suggests that clinicians have resorted to the use of combination antifungal therapy due to suboptimal treatment outcomes for invasive aspergillosis (IA). On the other hand, 22 reports the effectiveness of a therapeutic strategy using nebulized liposomal amphotericin B (LAmB) for Allergic bronchopulmonary aspergillosis (ABPA).

Consistency and Contradictions in Findings

There are still many challenges in treating aspergillosis. Treatment outcomes remain suboptimal, and new treatment approaches are needed. 13 . While a therapeutic strategy using nebulized liposomal amphotericin B (LAmB) for Allergic bronchopulmonary aspergillosis (ABPA) shows promise, further research is needed on its long-term safety and efficacy. 22 .

Practical Implications and Precautions

It is important to be vigilant in preventing and detecting aspergillosis early. Immunocompromised individuals and those at high risk for aspergillosis should consider regular checkups and prophylactic treatment. , 18 . When receiving treatment, follow your doctor's instructions carefully and be aware of potential side effects.

Limitations of Current Research

Research on the treatment of aspergillosis is still limited. Further research is needed on the effectiveness and safety of new treatment approaches, especially for Allergic bronchopulmonary aspergillosis (ABPA). There is also a lack of long-term follow-up data on ABPA treatment. 22 . Moreover, since diagnosis and treatment methods for aspergillosis can vary depending on the patient and their condition, more individualized treatment approaches are needed.

Future Directions for Research

To improve treatment outcomes for aspergillosis, the development of new treatment approaches and further research on the effectiveness and safety of existing treatments are necessary. 13 . Long-term safety and efficacy studies on a therapeutic strategy using nebulized liposomal amphotericin B (LAmB) for Allergic bronchopulmonary aspergillosis (ABPA) are also necessary. 22 . The development of new diagnostic tools for early diagnosis of aspergillosis is also crucial. , 18 .

Conclusion

Aspergillosis is a serious infection for immunocompromised individuals. Early diagnosis and appropriate treatment are essential for improving patient survival. , 18 . Researchers need to continue their efforts to develop more effective treatment approaches and new diagnostic tools. Individuals at high risk for aspergillosis should consider regular checkups and prophylactic treatment.

Treatment List

Combination antifungal therapy, nebulized liposomal amphotericin B (LAmB) maintenance therapy, polymerase chain reaction (PCR), early diagnosis, prophylactic treatment

Literature analysis of 32 papers
Positive Content
31
Neutral Content
1
Negative Content
0
Article Type
11
7
21
16
32
1.

A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis.

Author: StevensD A, SchwartzH J, LeeJ Y, MoskovitzB L, JeromeD C, CatanzaroA, BambergerD M, WeinmannA J, TuazonC U, JudsonM A, Platts-MillsT A, DeGraffA C

Improved allergic bronchopulmonary aspergillosis treatment

Allergic bronchopulmonary aspergillosis is a condition caused by an allergic reaction to a fungus. While corticosteroids are the main treatment, studies suggest that itraconazole, an antifungal medication, may be helpful as an additional therapy.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Language : English

2.

Azoles for allergic bronchopulmonary aspergillosis.

Author: WarkP, WilsonA W, GibsonP G

Improved ABPA control

This study discusses the treatment of Allergic Broncho-pulmonary Aspergillosis (ABPA), a hypersensitivity reaction to Aspergillus fumigatus that can complicate asthma and cystic fibrosis. The study emphasizes the role of oral corticosteroids in treating ABPA.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

4.

Azoles for allergic bronchopulmonary aspergillosis associated with asthma.

Author: WarkP, WilsonA W, GibsonP G

ABPA treatment
Exacerbation risk

Allergic Bronchopulmonary Aspergillosis (ABPA) is a serious complication of asthma and cystic fibrosis caused by an allergic reaction to the fungus Aspergillus fumigatus. While oral corticosteroids are the primary treatment, they don't always prevent flare-ups and may not stop lung function decline.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

5.

Azoles for allergic bronchopulmonary aspergillosis associated with asthma.

Author: WarkP A B, GibsonP G, WilsonA J

Allergic bronchopulmonary aspergillosis treatment

Allergic bronchopulmonary aspergillosis (ABPA) is a serious condition affecting people with asthma and cystic fibrosis caused by an allergic reaction to a common fungus. While oral steroids are the main treatment, they don't always prevent flare-ups and might not stop lung function from getting worse.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

6.

Azoles for allergic bronchopulmonary aspergillosis associated with asthma.

Author: WarkP A B, GibsonP G, WilsonA J

Allergic bronchopulmonary aspergillosis treatment

Allergic bronchopulmonary aspergillosis (ABPA) is a serious condition affecting people with asthma and cystic fibrosis caused by an allergic reaction to a common fungus. While oral steroids are the main treatment, they don't always prevent flare-ups and might not stop lung function from getting worse.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

7.

Pathogenesis of allergic bronchopulmonary aspergillosis and an evidence-based review of azoles in treatment.

Author: WarkPeter

ABPA treatment

This review examines allergic bronchopulmonary aspergillosis (ABPA), a condition that affects people with asthma and cystic fibrosis (CF) due to an allergic reaction to the fungus Aspergillus fumigatus. The review covers the causes, diagnosis, and treatment, including the use of antifungal medications, for this lung condition.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

8.

Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome.

Author: PattersonThomas F, BoucherHelen W, HerbrechtRaoul, DenningDavid W, LortholaryOlivier, RibaudPatricia, RubinRobert H, WingardJohn R, DePauwBen, SchlammHaran T, TrokePeter, BennettJohn E,

Aspergillosis treatment

This study investigates the impact of using other licensed antifungal therapies (OLAT) after initial treatment with voriconazole or amphotericin B deoxycholate for invasive aspergillosis. The study builds upon previous research showing the effectiveness of voriconazole for this fungal infection, and aims to understand how OLAT influences outcomes in these patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

9.

Poor efficacy of amphotericin B-based therapy in CNS aspergillosis.

Author: SchwartzStefan, RuhnkeMarkus, RibaudPatricia, ReedElizabeth, TrokePeter, ThielEckhard

Improve CNS aspergillosis

This retrospective study assessed the outcome of patients with central nervous system (CNS) aspergillosis treated with amphotericin B alone or in combination with 5-fluorocytosine or itraconazole, finding that treatment with amphotericin B and itraconazole had negligible efficacy.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

10.

Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis.

Author: WingardJ R, HerbrechtR, MauskopfJ, SchlammH T, MarciniakA, RobertsC S

Improved survival
Increased hospital-free survival
Reduced hospital stay

Voriconazole first-line for treatment of IA resulted in significantly fewer deaths and similar treatment costs. Hospital-free survival was significantly greater for patients initially treated with voriconazole.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

11.

Changes in causes of death over time after treatment for invasive aspergillosis.

Author: WingardJohn R, RibaudPatricia, SchlammHaran T, HerbrechtRaoul

IA therapy effectiveness assessment
Invasive aspergillosis

Most deaths due to invasive aspergillosis occur during the first 6 weeks after the start of therapy.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

12.

[Future role of micafungin in the treatment of invasive mycoses caused by filamentous fungi].

Author: Salavert-LletíMiguel, Zaragoza-CrespoRafael

Anti-fungal activity

This article discusses the potential future indications of micafungin, a echinocandin, based on in vitro studies, animal models, and small clinical trials.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : Spanish

13.

The role of combination antifungal therapy in the treatment of invasive aspergillosis: a systematic review.

Author: GarbatiMusa A, AlasmariFaisal A, Al-TannirMohammad A, TleyjehImad M

Treatment of invasive aspergillosis

Treatment outcomes for invasive aspergillosis, a serious fungal infection, are not ideal. This review examines the evidence for using a combination of antifungal medications to treat invasive aspergillosis.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

14.

Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis.

Author: ElphickHeather E, SouthernKevin W

Treatment of ABPA

Allergic bronchopulmonary aspergillosis (ABPA), an allergic reaction to a fungus called Aspergillus fumigatus, affects about 10% of people with cystic fibrosis. ABPA can worsen lung function. While corticosteroids are the main treatment, they have side effects and their long-term benefits are unclear. Antifungal medications like itraconazole and amphotericin B could be potential alternatives for treating ABPA, but further research is needed to evaluate their effectiveness in cystic fibrosis patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

15.

Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial.

Author: MorrisseyC Orla, ChenSharon C-A, SorrellTania C, MillikenSamuel, BardyPeter G, BradstockKenneth F, SzerJeffrey, HallidayCatriona L, GilroyNicole M, MooreJohn, SchwarerAnthony P, GuyStephen, BajelAshish, TramontanaAdrian R, SpelmanTimothy, SlavinMonica A,

Improved antifungal treatment

This study compares the effectiveness of a standard diagnostic strategy (culture and histology) with a rapid biomarker-based strategy (aspergillus galactomannan and PCR) in directing antifungal treatment for hematology patients at risk of invasive aspergillosis.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

16.

Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group.

Author: HerbrechtRaoul, PattersonThomas F, SlavinMonica A, MarchettiOscar, MaertensJohan, JohnsonElizabeth M, SchlammHaran T, DonnellyJ Peter, PappasPeter G

Accurate aspergillosis diagnosis
Effective antifungal treatment

This study re-categorized episodes of invasive aspergillosis (IA) from the Global Comparative Aspergillus Study (GCAS) according to the European Organization for Research and Treatment of Cancer/Mycoses Study Group consensus definitions, demonstrating the importance of consistent definitions for accurately assessing treatment efficacy.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

17.

Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis.

Author: ElphickHeather E, SouthernKevin W

ABPA treatment

Allergic bronchopulmonary aspergillosis (ABPA), an allergic reaction to a fungus called Aspergillus fumigatus, affects about 10% of people with cystic fibrosis. ABPA can worsen lung function. While corticosteroids are the main treatment, they have side effects and their long-term benefits are unclear. Antifungal medications like itraconazole and amphotericin B could be potential alternatives for treating ABPA, but further research is needed to evaluate their effectiveness in cystic fibrosis patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

18.

Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people.

Author: CrucianiMario, MengoliCarlo, LoefflerJuergen, DonnellyPeter, BarnesRosemary, JonesBrian L, KlingsporLena, MortonOliver, MaertensJohan

IA treatment

Invasive aspergillosis (IA), a serious fungal infection in people with weakened immune systems, is a major health concern. Early diagnosis and prompt treatment with antifungal medications are vital for survival. Treatments are given as prevention, based on diagnostic suspicion, or to treat confirmed infections. New diagnostic tools, such as tests that detect fungal DNA (polymerase chain reaction, PCR), and new antifungal drugs are urgently needed.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

19.

Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people.

Author: CrucianiMario, MengoliCarlo, LoefflerJuergen, DonnellyPeter, BarnesRosemary, JonesBrian L, KlingsporLena, MortonOliver, MaertensJohan

IA treatment

Invasive aspergillosis (IA), a serious fungal infection in people with weakened immune systems, is a major health concern. Early diagnosis and prompt treatment with antifungal medications are vital for survival. Treatments are given as prevention, based on diagnostic suspicion, or to treat confirmed infections. New diagnostic tools, such as tests that detect fungal DNA (polymerase chain reaction, PCR), and new antifungal drugs are urgently needed.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

20.

Developments in the diagnosis and treatment of allergic bronchopulmonary aspergillosis.

Author: AgarwalRitesh, SehgalInderpaul S, DhooriaSahajal, AggarwalAshutosh N

ABPA diagnosis
ABPA treatment
None mentioned

This review summarized the current evidence on the evaluation and treatment of allergic bronchopulmonary aspergillosis (ABPA), a complex pulmonary disorder.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

21.

Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis.

Author: ElphickHeather E, SouthernKevin W

Accelerated decline in lung function

This review evaluated the potential of antifungal therapies, particularly itraconazole and amphotericin B, as alternative treatments for allergic bronchopulmonary aspergillosis (ABPA) in patients with cystic fibrosis, considering the limitations of high-dose corticosteroids.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

22.

[Allergic bronchopulmonary aspergillosis: Evaluation of a maintenance therapy with nebulized Ambisome<sup>&#174;</sup>].

Author: GodetC, CouturaudF, RagotS, LaurentF, BrunA L, BergeronA, CadranelJ,

ABPA treatment

Allergic bronchopulmonary aspergillosis (ABPA) affects 3-13% of people with asthma and can cause serious breathing problems and lung damage. The goal of treatment is to reduce the frequency and duration of these problems. Current treatment with itraconazole and corticosteroids has limitations. This article discusses the potential benefits of using nebulized liposomal amphotericin B (LAmB), which delivers the medication directly to the lungs, potentially improving treatment effectiveness and reducing side effects.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : French

23.

Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial.

Author: KontoyiannisDimitrios P, SelleslagDominik, MullaneKathleen, CornelyOliver A, HopeWilliam, LortholaryOlivier, Croos-DabreraRodney, LademacherChristopher, EngelhardtMarc, PattersonThomas F

IA Treatment
Neutropenia

This post hoc analysis assessed the efficacy and safety of isavuconazole and voriconazole in neutropenic patients with invasive aspergillosis (IA). Isavuconazole had comparable efficacy and safety to voriconazole in neutropenic patients with IA. Resolution of neutropenia was associated with improved outcomes.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

24.

Systematic review and network meta-analysis of clinical outcomes associated with isavuconazole versus relevant comparators for patients with invasive aspergillosis.

Author: HerbrechtRaoul, KuessnerDaniel, PooleyNicholas, PosthumusJan, EscrigCesar

IA treatment

A study of patients with proven/probable invasive aspergillosis (IA) found that isavuconazole is as effective as AmB deoxycholate (AmB-D), liposomal AmB (L-AmB), and voriconazole.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

25.

Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people.

Author: CrucianiMario, MengoliCarlo, BarnesRosemary, DonnellyJ Peter, LoefflerJuergen, JonesBrian L, KlingsporLena, MaertensJohan, MortonCharles O, WhiteLewis P

Improved IA treatment

This updated review addressed the challenges of diagnosing and treating invasive aspergillosis (IA), highlighting the need for new diagnostic tools and drug treatment strategies.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

26.

Intravenous therapy for chronic pulmonary aspergillosis: A systematic review and meta-analysis.

Author: BongominFelix, AsioLucy Grace, OlumRonald, DenningDavid W

IV antifungals for CPA
Antifungal resistance
Major toxicities

Chronic pulmonary aspergillosis (CPA) is a potentially life-threatening debilitating lung disease necessitating long-term oral antifungal treatment. However, development of antifungal-resistant isolates of Aspergillus and major toxicities requiring discontinuation of treatment limits their use. Intravenous (IV) antifungals are an option in this group of patients. We comprehensively evaluate the response rates to IV antifungals in the management of CPA. We searched Medline and Embase databases to select clinical studies providing information about IV amphotericin B or an echinocandin for the treatment of CPA from inception to May 2020. Reviews, single-case reports and case series reporting &lt;10 patients were excluded. We evaluated 12 eligible studies. A total of 380 patients received amphotericin B (n&#160;=&#160;143) or an echinocandin (n&#160;=&#160;237) and were included in the meta-analysis. In a pooled analysis, overall response to IV antifungals was 61% ((95% confidence interval (CI): 52%-70%; I<sup>2</sup> &#160;=&#160;73.3%; P&#160;&lt;&#160;.001), to amphotericin B was 58% (95% CI: 36%-80%; I<sup>2</sup> &#160;=&#160;86.6%; P&#160;&lt;&#160;.001) and to echinocandins was 62% (95% CI: 53%-72%; I<sup>2</sup> &#160;=&#160;63.6%; P&#160;&lt;&#160;.001). Amphotericin B courses were usually doses at slightly &lt;1&#160;mg/Kg (deoxycholate) or 3&#160;mg/Kg (liposomal) for 2-3&#160;weeks. Micafungin doses varied from 12.5 to 300&#160;mg (frequently, 150&#160;mg) daily for at least 3&#160;weeks, and sometimes much longer. Liposomal amphotericin B was well tolerated, but led to renal function loss in 25% of patients. Adverse events were observed in 5-35.3% of patients receiving echinocandins, none of which was considered major. Intravenous antifungals have a place in the management of CPA. A head-to-head comparison of amphotericin B and echinocandins is lacking, and future studies should look at evaluating short- and longer-term outcomes of these agents.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

27.

Clinical experience with isavuconazole in healthy volunteers and patients with invasive aspergillosis in China, and the results from an exposure-response analysis.

Author: ZhangJing, ZhangYingyuan, WuDepei, CaoGuoying, HamedKamal, DesaiAmit, AramJalal A, GuoXuan, FayyadRana, CornelyOliver A

IFD treatment
Lower adverse events

Isavuconazole, a broad-spectrum triazole antifungal medication, demonstrated a favorable risk-benefit profile in Chinese patients. In a Phase I pharmacokinetics and safety study, no clinically relevant differences were observed between Chinese and Western participants, although exposure was increased in Chinese volunteers. In the Phase III SECURE study, the findings in Chinese patients were similar to the global population, with isavuconazole associated with a lower incidence of certain adverse events compared to voriconazole.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

28.

Impact of Surgical and Medical Treatment on Survival of Patients with Cerebral Aspergillosis: Systematic Review of the Literature.

Author: PajerHengameh B, AsherAnthony M, GelinneAaron, NorthamWeston, van DuinDavid, QuinseyCarolyn S

Increased survival

Early antifungal medical treatment and surgical resection were associated with increased survival for patients with cerebral aspergillosis.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

29.

Anti-fungal agents in the treatment of chronic pulmonary aspergillosis: Systematic review and a network meta-analysis.

Author: SehgalInderpaul Singh, DhooriaSahajal, PrasadKuruswamy Thurai, MuthuValliappan, AggarwalAshutosh Nath, ChakrabartiArunaloke, AgarwalRitesh

Itraconazole for CPA
Voriconazole for CPA

A network meta-analysis comparing the efficacy of different anti-fungal agents (AFAs) in treating chronic pulmonary aspergillosis (CPA) found that oral itraconazole and voriconazole are currently recommended in the initial management of CPA.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

30.

Nebulised liposomal amphotericin-B as maintenance therapy in allergic bronchopulmonary aspergillosis: a randomised, multicentre trial.

Author: GodetCendrine, CouturaudFrancis, Marchand-AdamSylvain, PisonChristophe, GagnadouxFrédéric, BlanchardElodie, TailléCamille, PhilippeBruno, HirschiSandrine, AndréjakClaire, BourdinArnaud, ChenivesseCécile, DominiqueStéphane, BassinetLaurence, Murris-EspinMarlène, RivièreFrédéric, GarciaGilles, CaillaudDenis, BlancFrançois-Xavier, GoupilFrançois, BergeronAnne, GondouinAnne, FratJean-Pierre, FlamentThomas, CamaraBoubou, PriouPascaline, BrunAnne-Laure, LaurentFrançois, RagotStéphanie, CadranelJacques, , GodetC, CouturaudF, CadranelJ, FratJ-P, BrunA-L, LaurentF, Marchand-AdamS, PisonC, GagnadouxF, BlanchardE, TailléC, PhilippeB, HirschiS, AndréjakC, ChenivesseC, DominiqueS, BassinetL, Murris-EspinM, RivièreF, GarciaG, CaillaudD, BlancF-X, GoupilF, GondouinA, FlamentT, CamaraB, PriouP, RagotS

Improved ABPA-related biological parameters
Increased risk of ABPA exacerbation

Nebulized liposomal amphotericin-B did not reduce the risk of severe clinical exacerbation in patients with allergic bronchopulmonary aspergillosis (ABPA).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

31.

Biologic drugs in treating allergic bronchopulmonary aspergillosis in patients with cystic fibrosis: a systematic review.

Author: MantiSara, GiallongoAlessandro, ParisiGiuseppe Fabio, PapaleMaria, MulèEnza, AloisioDonatella, RotoloNovella, LeonardiSalvatore

ABPA treatment
Adverse effects

Oral steroids and antifungal therapy are the standard treatments for allergic bronchopulmonary aspergillosis (ABPA) in patients with cystic fibrosis (CF). While these treatments are effective, they can also have significant side effects. Biologic drugs are being investigated as a potential alternative treatment for ABPA in patients with CF.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

32.

Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis.

Author: FrancisNatalie Z, SouthernKevin W

Antifungal therapy for ABPA in cystic fibrosis

This review examines the use of antifungal therapy, specifically itraconazole and amphotericin B, for treating allergic bronchopulmonary aspergillosis (ABPA) in individuals with cystic fibrosis. ABPA is an allergic reaction to Aspergillus fumigatus colonization in the lungs.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.